Cite
MLA Citation
Helen Lin et al.. “O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD).” Alzheimer's & dementia, vol. 14, n.d., p. P217. http://access.bl.uk/ark:/81055/vdc_100103406656.0x00001b